A Study of Treprostinil to Treat Interstitial Lung Disease Pulmonary Hypertension
Status:
Not yet recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to find out more about the drug treprostinil via
inhaler and the mechanisms of why patients with pulmonary arterial hypertension related to
Interstitial Lung disease (PAH-ILD) have limitations during exercise. The investigator is
studying treprostinil's effect on patients with PAH-ILD during exercise and its effect on
their quality of life after using it for 3 months.